Increase in Consolidated Net Sales
Consolidated net sales for the first half of fiscal 2024 was JPY 569.0 billion, a year-on-year increase of 4.2%.
Pharmaceutical Segment Performance
Net sales in the Pharmaceutical segment totaled JPY 113.8 billion, a year-on-year increase of 12.9%. Operating profit in this segment increased by 16.7% year-on-year.
Advanced Shipment of Influenza Vaccines
Advanced shipment of influenza vaccines contributed JPY 1.3 billion to the increase in profit.
Growth in Antibacterial Drug Sales
Sales of antibacterial injection increased, positively impacting the Pharmaceutical segment's performance.
Strong Performance of Domestic Business
Growth in sales, including high-profit items, is expected to continue in the second half, mainly driven by the domestic business.
Strong Growth in Hello Panda Brand
Hello Panda is expected to achieve JPY 19.9 billion in sales for the fiscal year, showing strong growth, particularly in the U.S.